Journal Article

Co-administration of ketoconazole to tacrolimus-treated kidney transplant recipients: a prospective randomized study

Khalid Farouk El-Dahshan, Mohamed Adel Bakr, Ahmed Farouk Donia, Ali El-Sayed Badr and Mohamed Abdel-Kader Sobh

in Nephrology Dialysis Transplantation

Published on behalf of European Renal Association - European Dialysis and Transplant Assoc

Volume 19, issue 6, pages 1613-1617
Published in print June 2004 | ISSN: 0931-0509
Published online March 2004 | e-ISSN: 1460-2385 | DOI: http://dx.doi.org/10.1093/ndt/gfh191
Co-administration of ketoconazole to tacrolimus-treated kidney transplant recipients: a prospective randomized study

Show Summary Details

Preview

Background. Since the introduction of calcineurin inhibitors, there has been a significant improvement in the results of solid organ transplantation, including graft and patient survival. However, high cost, chronic nephrotoxicity and other side effects stand as major challenges for long-term use of these drugs. The long-term safety and financial benefits of the combination ketoconazole–cyclosporine previously studied. However, data about the effect of the addition of ketoconazole addition to tacrolimus-treated patients are scarce. Therefore, this study was conducted to evaluate the safety and financial impact of that combination.

Methods. The subjects of this work included 70 live-donor stable kidney transplant recipients receiving tacrolimus. Their age ranged from 16 to 45 years. Among them, 54 were males and 16 were females. All of them were 6 months or more post-transplantation. Patients were randomly divided into two equal groups. Group I patients initially received ketoconazole 100 mg/day in addition to their usual treatment, while group II patients were considered a control. Patients were followed-up for 6 months.

Results. Concomitant ketoconazole–tacrolimus resulted in marked reduction of tacrolimus dose (by 58.7%) and cost (by 56.9%). It also resulted in significant improvement in graft function and fungal skin infection, in addition to a decrease of gastrointestinal episodes and hospitalization.

Conclusion. We conclude that ketoconazole–tacrolimus combination in kidney transplant recipients is safe, has outstanding impact on treatment costs and improves patient and graft outcome.

Keywords: ketoconazole; kidney transplantation; tacrolimus

Journal Article.  3125 words.  Illustrated.

Subjects: Nephrology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.